Our top pick for
AdvanSix Inc is a chemicals business based in the US. AdvanSix shares (ASIX) are listed on the NYSE and all prices are listed in US Dollars. AdvanSix employs 1,520 staff and has a trailing 12-month revenue of around USD$1.2 billion.
Since the stock market crash in March caused by coronavirus, AdvanSix's share price has had significant negative movement.
Its last market close was USD$17.61, which is 0.68% down on its pre-crash value of USD$17.73 and 118.49% up on the lowest point reached during the March crash when the shares fell as low as USD$8.06.
If you had bought USD$1,000 worth of AdvanSix shares at the start of February 2020, those shares would have been worth USD$615.53 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$924.88.
|Latest market close||USD$17.61|
|52-week range||USD$8.06 - USD$24.85|
|50-day moving average||USD$13.272|
|200-day moving average||USD$12.2867|
|Wall St. target price||USD$20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.908|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||0.28%|
|1 month (2020-10-23)||12.17%|
|3 months (2020-08-24)||28.35%|
|6 months (2020-05-22)||57.94%|
|1 year (2019-11-22)||-10.79%|
|2 years (2018-11-23)||-33.52%|
|3 years (2017-11-24)||-59.04%|
|5 years (2015-11-20)||N/A|
Valuing AdvanSix stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AdvanSix's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AdvanSix's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, AdvanSix shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
AdvanSix's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$87.8 million.
The EBITDA is a measure of a AdvanSix's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.2 billion|
|Operating margin TTM||2.49%|
|Gross profit TTM||USD$137.6 million|
|Return on assets TTM||1.49%|
|Return on equity TTM||6.14%|
|Market capitalisation||USD$419.3 million|
TTM: trailing 12 months
There are currently 487,334 AdvanSix shares held short by investors – that's known as AdvanSix's "short interest". This figure is 4.3% down from 509,389 last month.
There are a few different ways that this level of interest in shorting AdvanSix shares can be evaluated.
AdvanSix's "short interest ratio" (SIR) is the quantity of AdvanSix shares currently shorted divided by the average quantity of AdvanSix shares traded daily (recently around 194156.97211155). AdvanSix's SIR currently stands at 2.51. In other words for every 100,000 AdvanSix shares traded daily on the market, roughly 2510 shares are currently held short.
However AdvanSix's short interest can also be evaluated against the total number of AdvanSix shares, or, against the total number of tradable AdvanSix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AdvanSix's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 AdvanSix shares in existence, roughly 20 shares are currently held short) or 0.0212% of the tradable shares (for every 100,000 tradable AdvanSix shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AdvanSix.
Find out more about how you can short AdvanSix stock.
We're not expecting AdvanSix to pay a dividend over the next 12 months.
Over the last 12 months, AdvanSix's shares have ranged in value from as little as $8.06 up to $24.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AdvanSix's is 1.9492. This would suggest that AdvanSix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
AdvanSix Inc. manufactures and sells polymer resins in the United States and internationally. It offers Nylon 6, a polymer resin, which is a synthetic material used to produce engineered plastics, fibers, filaments, and films. The company also provides caprolactam to manufacture polymer resins; ammonium sulfate fertilizers to distributors, farm cooperatives, and retailers; and acetone, which is used by customers in the production of adhesives, paints, coatings, solvents, herbicides, and other engineered plastic resins, as well as other intermediate chemicals, including phenol, alpha-methylstyrene, cyclohexanone, methyl ethyl ketoxime, cyclohexanol, acetaldehyde oxime, 2-pentanone oxime, sulfuric acid, ammonia, and carbon dioxide. It offers its products under the Aegis, Capra, Sulf-N, Nadone, Naxol, and EZ-Blox brands. The company sells its products directly, as well as through distributors. AdvanSix Inc. was incorporated in 2016 and is headquartered in Parsippany, New Jersey.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.